RESUMO
BACKGROUND: Blood-tissue partition coefficients indicate how a chemical will distribute throughout the body and are an important part of any pharmacokinetic study. They can be used to assess potential toxicological effects from exposure to chemicals and the efficacy of potential novel drugs designed to target certain organs or the central nervous system. In vivo measurement of blood-tissue partition coefficients is often complicated, time-consuming, and relatively expensive, so developing in vitro systems that approximate in vivo ones is desirable. We have determined such systems for tissues such as brain, muscle, liver, lung, kidney, heart, skin, and fat. RESULTS: Several good (p < 0.05) blood-tissue partition coefficient models were developed using a single water-solvent system. These include blood-brain, blood-lung, blood-heart, blood-fat, blood-skin, water-skin, and skin permeation. Many of these partition coefficients have multiple water-solvent systems that can be used as models. Several solvents-methylcyclohexane, 1,9-decadiene, and 2,2,2-trifluoroethanol-were common to multiple models and thus a single measurement can be used to estimate multiple blood-tissue partition coefficients. A few blood-tissue systems require a combination of two water-solvent partition coefficient measurements to model well (p < 0.01), namely: blood-muscle: chloroform and dibutyl ether, blood-liver: N-methyl-2-piperidone and ethanol/water (60:40) volume, and blood-kidney: DMSO and ethanol/water (20:80) volume. CONCLUSION: In vivo blood-tissue partition coefficients can be easily estimated through water-solvent partition coefficient measurements.Graphical abstract:Predicted blood-brain barrier partition coefficients coloured by measured log BB value.
RESUMO
BACKGROUND: Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyrosine kinases. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models in various hematological malignancies, indicating that pan-Aurora kinase and multiple kinase inhibition may have preferential antileukemic activity. This phase 1 trial determined the safety, pharmacokinetics, and preliminary antitumor activity of ilorasertib alone or combined with azacitidine in advanced hematologic malignancies. PATIENTS AND METHODS: Fifty-two patients (median age, 67 years; 35 % with >4 prior regimens) with acute myelogenous leukaemia (AML; n = 38), myelodysplastic syndrome (n = 12), or chronic myelomonocytic leukaemia (n = 2) received 3 or 6 doses of ilorasertib per 28-day cycle and were assigned to arm A (once-weekly oral), B (twice-weekly oral), C (once-weekly oral plus azacitidine), or D (once-weekly intravenous) treatment. RESULTS: Maximum tolerated doses were not determined; the recommended phase 2 oral monotherapy doses were 540 mg once weekly and 480 mg twice weekly. The most common grade 3/4 adverse events were hypertension (28.8 %), hypokalemia (15.4 %), anemia (13.5 %), and hypophosphatemia (11.5 %). Oral ilorasertib pharmacokinetics appeared dose proportional, with a 15-hour half-life and no interaction with azacitidine. Ilorasertib inhibited biomarkers for Aurora kinase and VEGF receptors, and demonstrated clinical responses in 3 AML patients. CONCLUSIONS: Ilorasertib exhibited acceptable safety and pharmacokinetics at or below the recommended phase 2 dose, displayed evidence of dual Aurora kinase and VEGF receptor kinase inhibition, and activity in AML.